

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 586 333 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
19.10.2005 Bulletin 2005/42

(51) Int Cl.7: **A61K 45/06, A61P 35/00**

(21) Application number: **05090011.7**

(22) Date of filing: **20.06.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
LT LV RO SI

(72) Inventors:
• Siemeister, Gerhard
13503 Berlin (DE)
• Haberey, Martin
12169 Berlin (DE)
• Thierauch, Karl-Heinz
14159 Berlin (DE)

(30) Priority: **23.06.2000 EP 00250194**
28.06.2000 EP 00250214

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
01965012.6 / 1 292 335

Remarks:

This application was filed on 27 - 01 - 2005 as a
divisional application to the application mentioned
under INID code 62.

(71) Applicant: **Schering Aktiengesellschaft**
13353 Berlin (DE)

(54) **Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)**

(57) The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF

receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.




Fig. 1

Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., Cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al., Lab.

[0006] Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0007] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Gold-

man et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

[0008] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

[0009] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

[0010] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenic compounds.

[0011] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0012] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the

VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


[0013] A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Assoc. Cancer Res.* San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Assoc. Cancer Res.*, San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci.*, U.S.A.90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci.*, U.S.A.95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci.*, U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

[0014] Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

[0015] Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), *Cancer Res.* 59, 183-188 and Olson et al. (1997), *Int. J. Cancer* 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), *Prog. Natl. Acad. Sci.*, U.S.A.94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), *Cancer Res.* 58, 4646-4653).

[0016] Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I




20 in which

r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

R_3 und R_4 a) each independently from each other have the meaning of lower alkyl,


b) together form a bridge of general partial formula II,



40 wherein the binding is via the two terminal C- atoms, and

m has the meaning of 0 to 4; or


c) together form a bridge of partial formula III



55 wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;


G has the meaning of C₁-C₆-alkyl, C₂-C₆-alkylene or C₂-C₆-alkenylene; or C₂-C₆-alkylene or C₃-C₆-alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂-, oxa (-O-), thia (-S-) or imino (-NH-),
 A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,
 Q has the meaning of lower alkyl, lower alkyloxy or halogene,
 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
 X has the meaning of imino, oxa or thia;
 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygen atom, or a salt thereof.

[0017] A preferred salt is the salt of an organic acid, especially a succinate.
 [0018] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.
 [0019] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranil acid derivatives of general formula IV




in which

A has the meaning of group =NR²,
 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,
 Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group



or A, Z and R¹ together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

X

Y

p

R¹

R²

R³

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 - 3,

has the meaning of 1 - 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-

has the meaning of group -(CH₂)_p,


has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.



[0020] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0021] More preferentially compounds of genearel formula V




in which


R¹ has the meaning of group



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$

in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

R^2 has the meaning of pyridyl or the group



and

R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

[0022] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

[0023] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

[0024] Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of

the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

[0025] For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

[0026] The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

[0027] Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

[0028] Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

[0029] The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

[0030] The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

[0031] Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also

possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

[0032] For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

[0033] These formulations and application forms are also part of the instant invention.

[0034] Combined functional interference with VEGFNEGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGFNEGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGFNEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

[0035] The invention is also directed to a substance which functional interferes with both VEGFNEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGFNEGF receptor systems and Angiopoietin/Tie receptor systems.

[0036] VEGFNEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

[0037] Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

[0038] Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

[0039] The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

Example 1

[0040] Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

[0041] Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nulnu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase

inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl) [4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-ANEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

[0043] Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

[0044] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0045] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

[0046] The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

[0047] Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0048] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0049] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-ANEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

[0050] Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0051] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals re-

ceiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-ANEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0052] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

[0053] The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the VEGF/VEGFR receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

[0054] Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0055] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0056] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

[0057] Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0058] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0059] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure

6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

[0060] The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

Description of the figures

[0061]

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con. = treatment group 1
 mock+VEGF-A = treatment group 2
 sTIE2-c113 = treatment group 3
 sTIE2-c113+VEGF-A = treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

Sequence Identifier

5 <110> Schering Aktiengesellschaft

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

10 <130> 51867AEPMLXX00-P

<140>

<141>

15 <160> 59

<210> 1

<211> 1835

<212> DNA

<213> Human

20 <400> 1

ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60

agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120

25 tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180

actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240

tatacaaaaca gcaaaaaaac cataatggtg ccacagggat ggagcagga agggcatctc 300

taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360

agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420

aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480

30 aagaaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540

tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600

attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660

tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720

catttaagcg acaacaaaaa aaggcaaac ccaaacgca acctaacca agcaaaatct 780

35 aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840

gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900

aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960

gtgatcggtta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatag 1020

gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggagaca 1080

tccgccaaag tcatccttta tccgagtaa taactttaat tcttttctaa catttacag 1140

40 gcaaacagga atgcagttaa cgteccagtc cgtcccacgg ctgggctgcc gttccgtttc 1200

ctccacgaac gggtagcgcg ttcctatgaga aaggatatct ggcaatttta tattccacag 1260

tcaggtgggt ctgcgatagc tcatttaatg ttaaagcca tcaggggcct ctctcccgt 1320

ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380

gggggctggc tgctggctcc gagggggcat ccgcagtcgg tctggtcgtc tctcctgca 1440

ggctgggcag ctggccacca cttctccgac tcgaccctc caacaagcat cgcagggcac 1500

45 tgtcctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560

ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggtctttc tgctggtgct 1620

cttggacggg cgggtagttc tgctgcagag acaaagcat tccccttccc ttccgggctg 1680

atcttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740

cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800

50 gagacgaacc acgcccgggg gtgcggaagc ggccct

<210> 2

<211> 581

<212> DNA

55 <213> Human

EP 1 586 333 A2

<400> 2

```

5   gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctacccag 60
    acactaaca cagtccttat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
    tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgacctgtg 180
    agtgcacaca cctggaaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
    tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
    ttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
    agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
10  aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480
    aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttagggccct 540
    cacctcccca tgacatcctc catgagcctc ctgatgtagt g

```

<210> 3

<211> 516

<212> DNA

<213> Human

<400> 3

```

20  tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
    tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
    gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
    ttgttaagct tcgtggccag agtactgatt ctcttcaca gactatatgt cggaaaccaa 240
    agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
    tctcgcatc tgacaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
    atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420
25  tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcatg 480
    atgaagttcc agagtttgtt gtgtaaaagtc cgtctg

```

<210> 4

<211> 1099

<212> DNA

<213> Human

<400> 4

```

35  cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggccaggt 60
    cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
    ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
    ggggtgcgtc ttggccttgc cgtgccctca tcccccggtc gaggcagcga cacagcaggt 240
    gcaccaactc cagcaggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
    tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcagggtg 360
    ctgctgggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
    ggaagcctgc ctctagcaca ctcttgagga gcacactggc gacatagggt cccatcagtg 480
40  ctcccgcat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540
    cggccgccag cgcccgctcc acctgtgggt ccttggccgg cagtgccgcg agctccccct 600
    ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
    ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
    aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
    actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
45  agagcaccgt cagccagatc ttaccaccca cggtcgagtg ctctggacc tgggtccagca 900
    acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
    gcacgtcagt gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcagggag 1020
    gtctgccacg cccgttctac cgcctgctg ccgggcggcc caggtggagg tggggacgat 1080
    ggcggagtg acgcccgcg

```

<210> 5

<211> 1015

<212> DNA

<213> Human

<400> 5

```

55  gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

```

EP 1 586 333 A2

5 aaaaagtgct ttttgaaaa gttgaggttg aaatgatggg aaccaacatt ctttggattt 120
 agtgggggagc ataatagcaa acacccccctt gggttcgcaca tgtacaggaa tgggacccag 180
 ttgggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tgggtccgcag acaccccggt atgtcagcat cccccgacct 300
 gccttctggc ggcacacctc ggggtgctgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgtct ggaacagggt gcagggggcca agcgttctct cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgtgtc caggacagg 480
 gtcccttcag tcctctgtgt atgacctcaa gtccactctg ggccctgcag cccagcctgt 540
 gttgtaacct ctgctcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 10 aatgtgtctt cctccctggg gtctccacag cttccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aaccccgagg gcttcggccc agaccacagc gtcttgccct 780
 gaggcttaga cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tcctgttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900
 ctctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgttca cgtgctagt 960
 acgtttttct tcttacacat gaaaaataat gcataagtgt tagaagaaaa aaaaa
 15 <210> 6
 <211> 2313
 <212> DNA
 <213> Human
 20 <400> 6
 ccagagcagg cctggtggtg agcagggagc gtgcaccgga cggcgggatc gagcaaatgg 60
 gtctggccat ggagcacgga ggggtcctacg ctcgggcggt gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcctc atcatcctg 180
 ggctcgtgct cttcatggac tatggcaacg tgacagtgag cacagagtc aacctgcagg 240
 25 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca ccgcgcgcaa ggatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcag ctggaccgca tcaatgccag cttccgccag tgccagggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcattgctga 540
 atcagaagggt gaagacgctg gagggtggaga tagccaagga gaagaccatt tgactaagg 600
 30 ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctggtt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcggc actggccaag gagcaactgc aaaaggtgca 720
 agcctctgct ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag ctggcccggg gcctccgggc gcatatcgaa cgcgtggccc gcgagaagc 960
 35 agacctcaa cgccagaagc tggaagccca gcagggcctg cgggcccagtc aggaggcgaa 1020
 acagaagggt gagaaggagc ctacggcccg ggaggccaag ctccaagctg aatgctccc 1080
 gcagaccag ctacgcgtgg aggagaaggc ggtgctgcgg aaggaaacag acaacctgac 1140
 caaggagcag gaagagaaga agaggagggc ggagcagctc aggatggagc tggccatcag 1200
 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaa 1260
 gccccatggc cctgtcccca acccccagcc catcgacca gctagcctgg aggagttcaa 1320
 40 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggg tccaggcctg aggaccaagg gatggcccga ctcgccggtt tgcggaggat 1440
 gcagggatat gctcacagcg cccgacacaa ccccctcccg ccgcccccaa ccaccaggg 1500
 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcacccgag 1560
 cctcacgac cctcaccag agcacacggc cgcggagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 45 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860
 acaacacaca ccatgacaac gacacctata gatattggac caacatcaca tgcacgcatg 1920
 cctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgaccctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccgc acagccctg gccccagcac 2040
 50 ctcccctcct ccagcttctt ggctcccag ccacttcctc acccccagtg cctggaccgg 2100
 gagggtgagaa caggaagcca ttacctccg ctccctgagc gtgagtgttt ccaggacccc 2160
 ctcgggggccc tgagccgggg gtgaggggtc cctgttgtcg ggaggggagc cactccttct 2220
 ccccaactc ccagccctgc ctgtggccc ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaa aaaaaaaaaaaa aaa
 55 <210> 7
 <211> 389

EP 1 586 333 A2

<212> DNA
<213> Human

<400> 7

5
gccccaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
10 gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
15 <213> Human

<400> 8

tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
20 gaagcaggaa gcaagccac tcaaacgtga aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

<210> 9
<211> 561
<212> DNA
25 <213> Human

<400> 9

aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttcccttgc 120
30 tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaa ataccatca ttgtgattaa 420
ttaaaccctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
35 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

<210> 10
<211> 1508
<212> DNA
40 <213> Human

<400> 10

cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
45 gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcactct tctcctccgg gcctgttgcct gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
50 tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt ccctcttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaaagt tcccactgtc ccccttagga actttgaaaa accaaccatag 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataacttttg cactgttaat agaaagtgtg gatagctctt 840
60 gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatag cttgttagaa 900
ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960
55 ctaaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020

EP 1 586 333 A2

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatataa taatatTTTg aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaaat tatactaata tgttgtacat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataTTTt 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaTt 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 10 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 <400> 11
 15 gggcagggtga tcagggcaca catttcccgT ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgccccgac 120
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 20 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagtttttg 360
 acctcggccg cgaccacgct gggTaccga
 <210> 12
 <211> 981
 <212> DNA
 25 <213> Human
 <400> 12
 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 30 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcacaaa tacaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatatcat tataatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcccta 480
 35 ctcaatttcc ttctcagtc ctttttaact tttaaacagc taatcactcc catctacaga 540
 ttaagtggtg taatgccacca aaaccttttg ccaccttaa aatttctctc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtgt agtcaagccg actctccata cccaagcaag tcattccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 40 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcaccagca ccatacctca caggagtcca ctcccacgag ccgctgtgat 960
 ataagagttc ttttgatgac g
 <210> 13
 <211> 401
 45 <212> DNA
 <213> Human
 <400> 13
 50 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctcccc agacgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaactctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t
 55 <210> 14

EP 1 586 333 A2

<211> 1002
<212> DNA
<213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
tttgaaaatg ttaaatacaa gtccatttct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgcaggatt ctataaaagc caagttaact 240
10 gaagtaaata tctggggccc atcgccccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcat ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaaa aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
15 attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatc ttggttaggtc aggagtggga acccaaatc aattctttta 960
20 acaaacacta aagggtgattc taacacaggc ggtgtgagga cc

```

<210> 15
<211> 280
<212> DNA
<213> Human

25 <400> 15

```

cgaggtgggc caccogtgtc tggctctgaga tttttaaatg aggattacat taccctattt 60
ataatattcc tattctaadc tattgtattc ttacaattaa atgtatcaaa taattcctaa 120
30 aaacattatt agaacaacac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgttagtggt tgtaaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

```

<210> 16
<211> 2041
<212> DNA
<213> Human

35 <400> 16

```

ccccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
40 atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctca gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
45 aaaactgaag atagaccatt taaatgcttc taccaaaatt aacgcagctt aattaggac 480
caggtagata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
ataaaaacaa gcaactgagt tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
tagatatttg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcattttgga ctctctcagg atcaaaatac gagtctgcca actgtattaa atcctcctcc 780
50 accccctcca ccagttggtc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggccggg gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaaaaaaaa acccattcct 1140
55 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtggtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

```

EP 1 586 333 A2

5 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtgccc tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gttttctcag ctttttgcaag agaggcacag ttttcacaat aatattggtt atcaccagta 1680
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaagggtg tggtttcacc 1740
 tcccggtttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800
 agtggtttca gaacagttaa actcattagg aggactgcct atgggttttt cattcacaag 1860
 10 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaagatg ctgtaaaggc 2040
 t
 <210> 17
 <211> 235
 15 <212> DNA
 <213> Human
 <400> 17
 20 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccctc 60
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120
 agatactcag gagactgagc cacttgagcc caagaagttc aaggttacag 180
 tgggccacga tcatgtcatt aactccagc ttgggtgaca aaatgagact gtcta
 <210> 18
 <211> 2732
 25 <212> DNA
 <213> Human
 <400> 18
 30 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttgggtga tcacattgtg caaaatgggt aagcattcaa acactttgaa 180
 accagattct agcagggttg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtcctttgg gttgcttttt attaatgagg agactattgt 300
 gatggcataa ctcttcacta tatttaatgc tttccaggga gtgttcattt tcacttttca 360
 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 35 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgctcgc tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540
 gagaaaaaaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaagggtgc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660
 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagt 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaaggggtg 780
 40 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cacgctacca gtcaaacctg tgattggag tagcagcag gaagatgatg 960
 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtct gagctccatc 1020
 acaaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080
 agaagaaaag gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 45 aagatcacct acagtcccc aacagagact ctctttatag aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agcctgaca tggagaaga cctctctccc tccaggagga 1260
 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440
 50 aatcatcacg ctaaggaatt ccaagggcca catgagagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560
 tgggtgaaaa aagatgactg aaccttgcaag ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgtatat acacagagta tactaaagt aattatttgt tacaagaaa agagatgcca 1680
 gccaggatatt ttaagattct gctgctgttt agagaaattg tgaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 55 ttttagggcc tgcattgtat tatatacag acgtaggctt taaaatcctg tgggacaaat 1860
 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatacag 1920
 tttgcagttc actgcaaatc ttttacatta aggcaaaagat tgaaaacatg cttaaccact 1980

EP 1 586 333 A2

5 agcaatcaag ccacaggcct tatttcatat gtttccctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 aaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcattt tcaacttctt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattactttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460
 tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 actcttccat attccttctg cctatattta gtaatttaatt ttttttatga taaagtctta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaataa 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

<210> 19
 <211> 276
 15 <212> DNA
 <213> Human

<400> 19

20 ctccctaaat gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccctata 120
 tattccctat atagcaaaac aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg cgaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

25 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

<400> 20

30 attgtaccag ccttgatgaa cgtggggccct gcttcgcttt tgagggccat aagctcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgtga ccggaagggt tctcccaagt 120
 cagagttttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240
 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 35 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgcccaagag ccagcatctg gacagtgatg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatataat cgaaccattg 480
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600
 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660
 40 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaaggtc ctccggcagg 720
 ctggctacta ctcccagtc ctgtatctgg cggagaacca tgcacatcat gagtgggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840
 tgctttttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900
 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgatagggag gccccaggct gcagggccaa ctctgaggag ttcatcccca 1020
 45 tctttgccaa taaccgcgga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 gtggctcgct ctgcgacgtc tttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatgggtg cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcaggcca tcagcgtgtg tgagcgccat ggggagcagg 1380
 50 accctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 tgggtgcagac cctggcccaac aactccacag ccacactctc cgtcatcagg gactacctg 1560
 tccaaaaaac acagaaaacag agccagcaga ttgcacagga tgagctcgg gtgcggcggt 1620
 accgagagga gaccacccgt atccgcccagg agatccaaga gctcaaggcc agtccctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 55 tctgtgtgg ccactccttc caccaacact gctttgagag ttactcggaa agtgatgctg 1800
 actgccccac tgcctcctc gaaaaccgga aggtcatgga tatgatccgg gcccaggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

EP 1 586 333 A2

ctgtgattgc tgactacttt ggcagagggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaattgt cacagccctc acaagactaa agcgggaactt tttcttttcc 2220
 ctggccttcc ttaatttttaa gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttgaaaaaaa aagctggttt c

 <210> 21
 10 <211> 179
 <212> DNA
 <213> Human

 <400> 21

 15 aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaaactg agagaaacct acaacacaca gcagttagcc ctggaacagc 120
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

 <210> 22
 <211> 905
 20 <212> DNA
 <213> Human

 <400> 22

 25 tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaaag gtccaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaagg 180
 caaagggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccaccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggtcatt aataactatg aatatactct ttagaagggtg accattttgc actttaaaagg 360
 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 30 gggagctgga agagccttgg aagtttctat tacaaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgaag 540
 gtctgaccag ttcttggttaa caaacataca tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660
 ggcagggtct cctaattgtcc attattacat ttccattccg aatgccagat gttaaaagt 720
 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgcca gtccacagag 780
 35 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaat 900
 gttga

 <210> 23
 <211> 2134
 40 <212> DNA
 <213> Human

 <400> 23

 45 ggtctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120
 cattagaagt aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctacccct cagcagctc 360
 50 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaggt 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatcctaat gcttcactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt ttttctctca 660
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttatttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780
 55 tagaataaat gtataaacat tctctgaaac catagcagcc ataaacagt ctgggtcaag 840
 atcctatttg tactccttct tccccccatt gttagttagg taaagtaaaa cagggtcttag 900

EP 1 586 333 A2

5 taaaatctca cttttctcct acttttccatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgccogg ggctttatta 1080
 tgctatatca ctgctcagag gtttaataatc ctactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataaatcc cactttactg 1200
 atacacctca ctgggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttccctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagttctatga aatgttttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 10 ggtctgcaca aggtctgggt ctggctgggt tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcgcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taatttttagg tcgaagggca ttgccacag 1740
 taagaacctg gatggtcaag ggctcttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860
 15 tggacaaagt gtagtacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gtccctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 tttttttaca agtagatcca tttccccgcg aaacaccaca tttatcaaac ttcttttttg 2100
 agtctatgat gcgatcacia ccagctttta caca
 20 <210> 24
 <211> 1626
 <212> DNA
 <213> Human
 <400> 24
 25 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatatttttg 60
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120
 attagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 30 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctctgtgac tgaatacttc ggcaacttta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata ttgttagagc ttgctgtagaa tggattacat 420
 ggtagtgtat cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgaagcata tctgaattta cttataaaag atggtttttag 540
 aaagctttgt ctaaaaattt ggctaggaa tggttaacttc attttcagtt gccaaagggt 600
 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660
 35 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaaac tcagggttacc cttgaaggat atgctggcag 780
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 tctgggaatg attagttatg cctgttacca ttcccagaat ttcaaggggca tctgtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 40 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 45 tgtgtttggt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 tggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attataacct tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa
 50 <210> 25
 <211> 1420
 <212> DNA
 <213> Human
 <400> 25
 55 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

EP 1 586 333 A2

5 ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120
acacaagctt aagaaaaaacg agcaagggaag agtatcttca ttattctcat tttctctgag 180
ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
tccttgctact gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 420
atggtttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480
ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
tcagccttgc catgtatcag ttccacttga aatttgagac caattaaatt tcaactgttt 600
aggggtggaga aagagggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
10 atccttttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
tttgctctgt tttgcctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
accagtacct ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900
tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
15 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
togacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttgggt aggttactgt 1140
acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
tatataaatt tttatactg attggttcat agatggtcag ttttgtagac agactgaaca 1260
atacagcact ttgccaaaaa tgagtgtagc attgtttaaa catttgtgtg taacacctgt 1320
20 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
agtaaataaa gtgtccttta acttcaaaaa aaaaaaaaaa

<210> 26
<211> 689
<212> DNA
<213> Human

<400> 26

30 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
caaacaatta tagcacatcc ttctttttac tctgtctcac ctcccttagg tgagtacttc 120
cttaaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcctta 180
ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
cacttgtctc tgcaccattt atcacaccag gacagggctc ctcaacctgg gcgtactgt 300
catttggggc cagggtgattc ttctttgcaa gggctgtcct gtacctgccc gggcgccgc 360
tcgaagcgtg gtcgcgcccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480
35 gaggtggctg gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagttgt 540
tgtcaagatg ctgcattaaa tcaggcagggt ctacaaaggc atcccaagca tcaaacatgt 600
ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
cacaccaga gcctgaagtt tgtccttcg

<210> 27
<211> 471
<212> DNA
<213> Human

<400> 27

45 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
ccctctcgtc cattggtggc accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120
agccctaacc caggccccgc ccagggccac cagcaccact gcaaacaccg cacctgccta 180
ccagccacca gctgcctaca aagacaatcg ggcacctca gtgacctcg ccaccacagc 240
gggtacaggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
tgggctgggt cccggcgggg ctgtcaatgg aggcaggggt tccagcacaa agtttacttc 360
50 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

<210> 28
<211> 929
<212> DNA
<213> Human

<400> 28

EP 1 586 333 A2

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acgggttggc tgctgggtgg ctttccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccgga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggttccct 240
 gcctttcagt gccatctctg ttgagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttggcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggtg 420
 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttctctact cagttttcta 480
 10 ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
 cttactcact gggttatgtct tcttctcat gctgggcacc atctcctttt tttcttccct 600
 aaagtccatc cggatatctt atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgtgttt ctctcccttt ctctatgccc tgttgaactc tcctaccagc ttctctctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 15 taagttgcct ttagttttgg tctgtatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa
 <210> 29
 <211> 1775
 <212> DNA
 <213> Human
 20 <400> 29
 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120
 25 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggcttccagt ccgtgtgggg 180
 cgcccgctg gcttctcct cgtaggactc cccaaactcg ttactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaa acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgaactca actttagatt 420
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgaagagct 480
 30 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 cccgacacag agagggtaca gcaggatga caagtacttc atggcctgag tatcgtactc 600
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcactctca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cacggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgccttctt 840
 35 cttcttccag aaactgatgt catttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaa aaggtcagcg ccagggaagta taagttggta tctacaaaaa tctctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gcccagtgta gaccttgcg taggacacgg tgaggggag 1080
 ctcggtggtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctggctgat 1140
 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 40 cacatcgga ggcaggagg acccgtaaaa gacaaagttg tccgccatca cgttcagcgc 1260
 cagcccggt cgccagtggt aactggctc atccagggca ctgctcggt tcttctccgc 1320
 ctcgatctgc tgtgtatcag actcccggg gagcagggtt atttctctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 cccagcgtga tggaggaga ttaggcata cagcgtccca ttgtttctcg ttttctttg 1500
 tacagaaaaca ttaactgtcc tttcaaatg ggactccaca tcaaagtctt ccacattcaa 1560
 45 gaccaggtcg atgtgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgcccgc ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcgggtgtag acgatgccgt acatgacca gcaggtgtgc accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gcccc
 <210> 30
 <211> 1546
 50 <212> DNA
 <213> Human
 <400> 30
 55 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

EP 1 586 333 A2

	acaccatcta	cgggcaccat	ggaactgctt	caagtgacca	ttctttttct	tctgcccagt	180
	atttgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacacaaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaagggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcacac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaa	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaaagt	ctgcagaatc	1020
	aatcccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagttagg	1080
15	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcggt	cctaggaaaa	ggaattttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
	actttcctta	atgttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
20	gcagggaaaa	gttgacacgtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatatata	gtatttttatt	cctgctttctg	tgttactttt	aataaataac	tactgtactc	1500
	aataactctaa	aaataactata	acatgactgt	gaaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
25	<213>	Human					
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
30	aagggaagt	cctctgatgg	ccaaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	ccacttaaa	cagaacgtta	cggatatttc	tggttttgcc	attggtatgc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
35	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactattttc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccac	ggtcttgtaa	aaaggaagtc	tgaatacaga	gcccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatcatcaa	cacagacacg	atttggactc	cctgacaggt	660
	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tattttgtcac	cacggtcccg				
40	<210>	32					
	<211>	1620					
	<212>	DNA					
	<213>	Human					
	<400>	32					
45	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgctcctttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
50	tttaagtata	aagacttaga	aaactagaat	aatgtcttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
	aaaaaaaact	tttaacattt	aaaaataaaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaagagaa	ataaggctga	ctgaatgttt	480
	tcataatttt	tcacacaata	acagtccctt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
55	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
	tggaagtgtg	cacaaaaatt	aggatcatgc	ttcagtgtct	tggttcttta	acctaccctt	720
	tgacaatcag	gtgctaata	ttgtatacta	ttaaaaccag	cacataagta	ttgtaatgt	780

EP 1 586 333 A2

5 gtgttcctcc taggttgga gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
 gtcagttgtg tcttttcacc tcgattttgt aattaataga attgggggga gaggaaatga 900
 tgatgtcaat taagtttcag gttttggcatg atcatcattc tcgatgatat tctcactttg 960
 tcgcaaatct gcccttatcg taagaacaag tttcagaatt ttccctccac tatacgactc 1020
 cagtattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgccagaa 1080
 aaatctgtcc tttttggtac caaacctgag gtcttttgga agataatgta gaaaaccact 1140
 acctattgaa ggcctgtttt ggctaactctg tgc aaactct gatgatacct gcttatgttg 1200
 attcttttcc acactgcttt catttttaag tataaagact tagaaaaacta gaataatgct 1260
 tttacaataa attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320
 10 atttaaacia gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
 ccaaatcaaa aacccaacgc gtaaaacagg gcagtatttg tgttcctaata tttaaaaagc 1440
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500
 acatacagca ttgtacatta caatgaaat gtgtaactta agggatttat atatatataa 1560
 acatatatac ctttgaacc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620

 15 <210> 33
 <211> 2968
 <212> DNA
 <213> Human

 <400> 33

 20 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggtattca 180
 gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
 gatgatgac ggactaaaga agaaagggtc tatgacaaag caaaacggag gattgagaaa 300
 25 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
 gtactttggc atgtggacac aggggaagaca aaaattctag ataagctccg tcacacacat 420
 gtacaagatg gtgaagcagg tggatcaca caacaaattg gggccacca tgttctctct 480
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
 ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
 30 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
 aataagattg ataggttata tgattgaaa aagagtcctg actctgatgt ggctgctact 780
 ttaaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840
 gtactttgat cacagcagg tttgaatgct gctttgtttt atgagaataa agatccccgc 900
 acttttgtgt ctttggatcc tacctctgca catactggtg atggcatggg aagtctgac 960
 taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgaca ctgtgaagag 1020
 35 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080
 atcttctgat atcagcagg gaaggaagga gatacaatca ttgttctctg agtagaaggc 1140
 cccattgtaa ctgagattcg aggcctcctg ttacctctc ctatgaagga attacgagt 1200
 aagaaccagt atgaaaagca taagaagata gaagcagctc agggggtaaa gattcttgga 1260
 aaagacctgg agaaaacatt ggctggttta cccctccttg tggttataa agaagatgaa 1320
 atccctgttc ttaaaagatg attgatccat gagttaaagc agacactaaa tgcctatcaa 1380
 40 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440
 gaatttctga aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500
 aaagatgtta tgaaggcttc agtgatgttg gaacatgacc ctgagtatgc agtaattttg 1560
 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatatgtt aggagttaga 1620
 attttttagt cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
 45 atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800
 gcaggtcagg tgaacacagg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860
 ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920
 gaagtttgtg taaaaataga acctatccct ggtgagtcac ccaaaatggt tggagacat 1980
 tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaa 2040
 50 gacttggtca gagatgaaat ttttcacatg gacggcagc ttattgtgga gctgaagaaa 2100
 gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160
 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220
 gacttaagta tggaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280
 aacttacact gttttgacag tggtcagtta catgtccca cagttccaat gtgcctgttc 2340
 actcacctct cccttcccca acccttctct acttggctgc tgttttaaa tttgcccctc 2400
 cccaaatgtg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460
 55 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattctttg gacttttttg 2520
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagcattct 2580
 tctgccatat gccttttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

EP 1 586 333 A2

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaaat catcaccaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgtaggctt tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 ggtatgccag cacctgggta acagtaggag attttatata ttaatctgat ctgtttaatc 2940
 tgatcgggtt agtagagatt ttatacat

<210> 34
 <211> 6011
 <212> DNA
 <213> Human
 <400> 34

15 acggggcgcc ggacgaccgg cacatcttat cctccacgcc cactcgcac tcggagcggg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgccggcc 120
 cggcttgagc cgagcgagc acccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180
 tgccgggaga aacttttttc tttttccccc ctctcccggt agagtctctg gaggagagg 240
 ggaactcccc cggcccaagg ctctggggt cgggggtcgg cgccgcgaga aggggcccgg 300
 20 tccgccccgg aggggagggg cccccgggga cccgagaggg ggtgaggac cgcgggctgc 360
 ttgtgcggcg cggcgagcgt gtgccccgcg caggggaggc gccgccccgc tccccggccg 420
 gctgcgagga ggaggcgcg gcggcgaggg aggatgtact tgggtggcgg ggacaggggg 480
 ttggccgggt gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540
 tccggcaccc gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagccagg 600
 25 aaccgccccg ggagcatcgt gcaggcgctc tgccgctgct gctacacgt cgccagccag 660
 ggaacagaga gctgcggcg caccttcggg atttacggaa cctgcgaccg ggggctgctg 720
 tgtgtcatcc gcccccgct caatggcgac tccctaccg agtacgaagc gggcgcttgc 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcccttcag ctttaaagag aattgaagaa 960
 30 gagaagccag attgctcaa ggccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtccctt acccagccgc 1080
 tgctgtgtca acccgagcgg ctgtctgcgc aaagtctgac agccgggaaa cctgaacata 1140
 ctatgtgtca aagcctcagg gaagccggga gagtctgtg acctctatga gtgcaaacca 1200
 gttttcgggc tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320
 35 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtgcga tgggacacct ggaagtgtct gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccggc 1560
 cagtggtggt agataaactg cgagaggtac tacgtgcccc aaggagagtg ctgcccagt 1620
 40 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680
 cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagt cgtcaacgg 1740
 gaacgccact gcgttcgcag cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagtgtatcc acctgcatgt 1860
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggtt caaacgcgat 1920
 cacaatggtt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggt ttccctactg atgccccaaa ctgtgagatc 2040
 45 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 ctttgattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 ctctcatgca gtaagatctg ccccttggtt ttccagcagg acagtcacgg ctgtcttctc 2220
 tgcaagtgcga gagaggcctc tgcttcagct gggccaccca tccgtgcggg cactgtgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 50 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgccgtgtgc 2400
 aacccacca ttcaccctgg acagtgtctc ccatcatgtg cagatgactt tgtggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc caccgcccgt gaggagaata ctttgtggaa 2520
 ggagaaacgt ggaacattga ctccgtgact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640
 55 tgctgcccac agtgtacaga tcaacctttt cggccttcc tgtcccgcaa taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 gcggtttgta ccagctgcat ctgcatgtat agcgtaatga gctgtttctc tgagtcctgc 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc actactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

EP 1 586 333 A2

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gacctctgc 3000
 tgcaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagtgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 aacctcgag gagaggttga cctggagggt ccactgtggc ccacgcctag tgaaaatgat 3180
 5 atcgctccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 caccacaagt aagattcttc actggactcc attgcctcag ttgtgggtcc cataattata 3300
 tgcctctcta ttataatagc attcctattc atcaatcaga agaaaacagt gataccactg 3360
 ctttgctggg atcgaacacc aactaagcct tcttccttaa ataatcagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccagggt gacagttccc agagaatgct aagaattgca 3480
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 agactctaaa tctgctctaa aaagtaaact agaatttgtg cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cacttttctc caagataact gaccaagtgt tttcttagaa 3780
 ccaaagtttt taaagttgct aagatatatt tgctgttaag atagctgtag agatatttgg 3840
 15 ggtggggaca cagtgtttgg atggggaaag gggtggagg gtggtggtgg gaagaaaaat 3900
 tgggtcagctt ggctcgggga gaaacctggg aacataaaaag cagttcagtg gccagaggt 3960
 tatttttttc ctattgctct gaagactgca ctgggtgtcg caaagctcag gcctgaatga 4020
 gcaggaaaca aaaaaggcct tgcgacccag ctgccataac caccttagaa ctaccagacg 4080
 agcacactaa aactccttga cagccatccc aggtctaaag ccacaagtgt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catttctcta 4200
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
 20 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatctcttg 4320
 atgtggagca tctgagctttg tttttttaca agctgacagg aagaggaggg agagggtgac 4380
 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440
 ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 gactgttttg ggattctttt tccttattat atactgattc tacaaaatag aaactacttc 4560
 25 atttttaattg tatattattc aagcactttt gtggaagctc aaaaaaatg atgcctcttt 4620
 aaactttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680
 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
 tgttttcctg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800
 cattccatag cagtgccttt gatcacttac aaatttttg aataacacaa aatctcattc 4860
 30 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
 attcctttat taaaatcttc ctcatcttga tttgctttca gttgggtttc aatttgctca 5040
 ctggccagag acattgatgg ctgcatcact aatcagctcc tggatttttt 5100
 tttttttttt tcaaacatg gtttgaacaa actactggaa tattgtccac aataagctgg 5160
 aagtttggtg tagtatgcct caaatataac tgactgtata ctatagtgg aacttttcaa 5220
 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280
 35 tgcctgttgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaa gaaactttcaa gtattgttgt aaatacttg acagagggtg ctgaacttta 5400
 aaaaaaatta atttattatt ataatgacct aatttattaa tctgaagatt aaccattttt 5460
 ttgtcttaga atatcaaaaa gaaaaagaaa aagggtgtct agctgtttgc atcaaaggaa 5520
 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaaataat ttgttaaatc 5580
 40 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760
 ttattatttt aaagatatga tttatcttga gtgctgtatc tattactctt ttactttggg 5820
 tctgttgttg ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880
 cacttgaggt gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940
 45 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 aaaaaaaaaa a

 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

 50 <400> 34a

 mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60
 gccytcasqg nescggtfqi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120
 55 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
 vqfsprcped svliegyapp geccpplsrc vcnpagclrk vcqpgnl nil vskasgkpg 240

EP 1 586 333 A2

5 ccdlyeckpv fgvdcrvec ptvqqtacpp dsyetqvrllt adgcctlprr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfr mdncrfrcrq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctltrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfqf ltdaqnceic ecrprpkker 540
 piicdkycpl gllknkhgcl icrckkkpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee swndgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvqg etwnidsctq ctchsgrvlc etevcppllc 720
 qnpsrtqdsq cpqctdqpfpr pslnrnnsvp nyckndegdi flaaeswkpq vctscicids 780
 10 viscfscscp svscerpvlr kgqccpypcl dtipkkvvch fsgkayadee rwdldscstc 840
 yclqggtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt nhrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgrtrqvq ssqrmlriae pdarfsgfys 1020
 mqkqnhlqad nfyqtv

15 <210> 35
 <211> 716
 <212> DNA
 <213> Human

20 <400> 35

25 gcagtagctg gagggtcctg cagggggaaa gccaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctgggcccgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtcagc agggatcagc cccagaacac accctcctcc ccgggacgac gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgaggggat ctcctgattc tctttatag acctcaaaact gaccatacta aacagtgtag 360
 aagggtcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgagg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 30 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

35 <210> 36
 <211> 395
 <212> DNA
 <213> Human

<400> 36

40 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcttttgcca tttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggttaacaa tgatcatttt caaaatgtta aaacccta 300
 tgcagttcct tttttaaat attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

45 <210> 37
 <211> 134
 <212> DNA
 <213> Human

50 <400> 37

ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

55 <210> 38
 <211> 644
 <212> DNA

EP 1 586 333 A2

<213> Human

<400> 38

```

5   aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
    cagtggcgct tgagttgggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
    ggggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
    ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaactgag 240
    gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
    ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaaga 360
10  aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
    ttcgcaccgg aaaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
    caagaggaaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
    tcaaaggctt ctttgaaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600
    gcagatggac tcagaggttg tggatgaaaa actaaggacc tcatt

```

<210> 39

<211> 657

<212> DNA

<213> Human

<400> 39

```

20  ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
    cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggg tcttggccca 120
    gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
    tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
    acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
25  agcaaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaaattc 360
    tggctccttg agcaaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
    ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
    aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
    taagaaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
    atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

<400> 40

```

35  acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
    ctggttagtt tttgtaggct cattatggtt agggctggtt agatgtatat aagaacctac 120
    ctatcatgct gtatgtatca ctcattccat ttcatgttc catgcatact cgggcatcat 180
40  gctaatatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
    ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
    atatgactaa cagcaactcc atcacttgag aagtataata gaaaaatagct tctaaatcaa 360
    acttccttca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420
    taagattcac tataatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480
    ccattccatc aatactttac aggatggcat ttaatacaga tatttcgtat tccccccact 540
45  gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
    tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
    actcagaact atatttctaa gcctgcattt tcaactgatgc ataattttct tagtaattt 720
    aagagacagt ttttctatgg catctccaaa actgcagtac atcactagtc ttacttctgc 780
    ttaattttat gagaaggat tcttcatatt aattgctttt gggattactc cacatctttg 840
    tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
50  attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
    tgagatctat atttataagc agccatggaa ttctatttat gggatgtttg caatcttaca 1020
    ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
    gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
    ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggg tatagaaatc 1200
    tggaaaataa aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
55  ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
    tgaaaaaa

```

EP 1 586 333 A2

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60
 tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120
 taacccccgg ctatcagtcc ggatgggtgc caccctcctt gctgtaggat ggaagcagcc 180
 atggagtgagg agggaggcgc aataagacac ccctccacag agcttgcat catgggaagc 240
 tggttctacc tcttctggc tctttgttt aaaggcctgg ctgggagcct tccttttggg 300
 tgtctttctc tcttccaacc aacagaaaag actgctcttc aaagtgagg ggtcttcag 360
 aaacacagct gccaggagcc caggcacagg gctgggggcc tggaaaaagg agggcacaca 420
 ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480
 gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
 tgcataagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
 gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatccaa 780
 aatagtctac ggcataacca ccctgaacgt gcctaacttc gtaagctaag cagggtcagg 840
 cctgggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900
 actctgtctt aacagttagc tggcacacag aaggcactca gtaataactt gttgaataaa 960
 tgaagttagc atttggtgtg aaaaaaa

<210> 42
<211> 956
<212> DNA
<213> Human

25

<400> 42

cggacggtgg ggcggacgcg tgggtgcagg agcaggcgcg ctgccgactg ccccaaccaa 60
 ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
 tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
 caggcgtgtg gcagccacac gcaggcggcc agggcgcca gggaccaaa gcaggatgac 300
 cacgcacctc cacgccactg cctcccccca atgcatttgg aaccaaaagc taaactgagc 360
 tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgtctctg acagatggac 420
 gcaggccctg tccagcccc agtgcgctcg ttcgggtccc cacagactgc cccagccaac 480
 gagattgctg gaaaccaagt caggccaggt gggcgacaa aagggccagg tgcggcctgg 540
 ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcgttgg 600
 gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
 tgaattaatt cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
 tttgtctctt gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
 tcgcaggacc aagggggcg ggactgctgg ctcacgcccc gctgtgtcct ccctccctc 840
 ccttccttgg gcagaatgaa ttcatgctg attctgtggc cgccatctgc gcagggtggt 900
 ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

<210> 43
<211> 536
<212> DNA
<213> Human

45

<400> 43

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
 cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
 agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
 tctaataaaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
 cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
 attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
 ctggaaaaag tgggttatgc cacttttaaa accctttctg gtaaatatta tggtagctaa 480
 agggctggtt ccccgccacc tggacctgga caggtagggt tccgtggtta accagt

55

EP 1 586 333 A2

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

10

15

20

25

30

```

ggggaggagac gagtatggaa cctgaaggt agcaagtcca ggcaactggc tgaccatccg 60
gctccctggg caccaggtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac cttagagag gtctcccagg ccagctcaag gtgtcccact 180
atcccctctg gaggaagag gcaggaaaat tctcccggg tccctgtcat gctactttct 240
ccatccaggt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatattccc ttagggccag gacttgggcc tccagctcat ctgttccttc tggggccatt 360
catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtgggtg gggctagttg gggttgaatt taggggccga 660
tgagcttggg tacgtgagca ggggtgttaag ttaggggtctg cctgtatttc tgggtcccctt 720
ggaaatgtcc ccttcttcag tgctcagacct cagctccagt gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcttggg 840
gcccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtcccagggt gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt ctagagggtc agaatttag ctccaggatc agctgggggt 1020
atggaattgg gctgagatga aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagtg 1140
aggctggaag gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttgggaatg 1200
aaagagtgac cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
gaagggtgctc ttactcagtt aatgatgagt gactatatat accaaagccc ctacctgctg 1320
ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtatcataga ggatccattt ctacctgcat ttcccagggt 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgccctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
cctcttgccct cttgtagaat gcagctcttg cctcaataa atgcttcctg cattcatctg 1620
caaaaaaaaaa

```

<210> 45
 <211> 169
 <212> DNA
 <213> Human

35

<400> 45

40

```

tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggg ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagtgtga

```

<210> 46
 <211> 769
 <212> DNA
 <213> Human

45

<400> 46

50

55

```

tgcaggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaaag cagcgggtgga 60
atttgtcgct ttcaactttt ataaagtgtc acataaaatg tcatattttc aaatttaaaa 120
acataactcc agttcttacc atgagaacag catgggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaaacaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
aagggtgact aggcaatctt agagatctgg caacttatat tatatataag gcatctgtga 300
ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcataata tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc ttctctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa ttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
ttgatataag tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

```

EP 1 586 333 A2

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
<211> 2529
<212> DNA
<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
gtgaaaatta gtgactgggt aagggtgtgcc actgtacata tcatcatttt ctgactgggg 120
tcaggacctg gtcctagtc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
gccttactta gctcctggca gagggtagt ggggacctac gaggttcaaa atcaaatggc 360
atttgccag cctggcttta ctaacaggt cccagagtgc ctctgttggc tgagctctcc 420
15 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctacct acaacttttc 480
attattcttc tggaaaccca tttctgttga gtccatctga cttaagtct ctctccctcc 540
actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
ccagaggccc ctgcaacttt gcggatttcc agaaggtagt aaaaagagca ctcttgagt 660
ggtgcccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttctctac 720
caagtggatt cggcatatga accacctact caatacttta tttttgtct gtttaaacac 780
20 tgaactctgg tgttgacagg tacaaaggag aagagatggg gactgtgaag aggggagggc 840
ttccctcatc ttccctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
gcaatagatg ggccttccca ccatttgttg gttattgctg ggggttagcca ggagcagtgt 960
ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020
ccagaaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
agggtgaacag tcctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
25 ttatgaaact gaaaatcaaa tcaaggtatt ggaagaata atttccctc gattccacag 1200
gaggggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
caaggagttt tcagggaact ctatcaagcc atacaaaat cagggtcaca tgtgggtttc 1380
ccctttcctt gcccttctat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440
gcagttgggc tgacctgaca aagccccagc tttcctgttg caggttctgg gagaggatgc 1500
30 attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560
tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagttctcag 1620
cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
agggagaaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
tgccaggaaa ccaggaagtc attcaagtgg ttctctgagg ccaaagacac tgagcacagc 1800
ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
35 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
gggggagtgagg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
tgaaaatttc cagaaatacc atttgggtgca tccctttgtt tctgtaatat taaactcagg 2100
tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
40 gcctgaagtt atagagtgtt tacagcggtg gcgatattca ggggtcatcg ccaactggtc 2280
tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtacca 2400
gtccagagcc ctgccacgga tgtacgcagg agccagcat taggcaatca ggagccagaa 2460
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
45 ggggtgtcc

<210> 48
<211> 1553
<212> DNA
<213> Human

<400> 48

55 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
ttcatatata tatatacata catatatataa ggaaacaatt tgcaaattta cacacctgac 120
aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
ctagccaggc ccgtttttcca tccctaagta ccattctctc atttggggcc ttctaggggt 240
ggggccctga gcttgggttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt ttacgtgat 360

EP 1 586 333 A2

ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggctaata tcacctgaac 420
tcgaaaaacag cgcccagcct cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480
gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540
agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
5 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
10 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
aggctaccca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaac 1080
aaaaaacacg tcttgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
ggatgagctt cactcaacgt ggagatgggt gtggactggt ccctgaaaag cgggccttgc 1200
agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
cgaggggagc gaggaggctt tctctagtcc ctttgaggc tttggctgag agaagagtga 1320
15 gcaggggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgcc 1380
tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49
<211> 921
<212> DNA
<213> Human

<400> 49

25 ctgtgtgctcc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttgga 60
tggttcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaaacc 180
gcctgtcaga acacttggt actcctaccc cagatcagtg gacctgggaa tgagggttg 240
tcccgggagg cttttctcca agctgttgcc accagaccg ccatgggaac cctggccaca 300
gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
30 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
tgcgtgcctg tgtgtgtgag tgcccctccc ctgcagcgt cgggtggtatc tccctccagc 480
cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagact 540
ccacgtggtt ttaaggggag acctttccct ggacctggg gtctcgccgt atctcatgac 600
cagggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
gtcccgtga cctgccccg tggcgtctca cggtgatgcc tgctcctgac attggtgttc 720
35 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
tactttgacc tcttgccctac aacccttcc ttgggtccga ggtggttagc tttgttact 900
tcagatggtt gggggcgggt g

<210> 50
<211> 338
<212> DNA
<213> Human

<400> 50

45 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
tcccttccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120
catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
aacgacctag cctgggtaga aacaaatgtc agcatgata catactcaat gatccttctg 240
cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgc atttgctaca 300
50 gtaagaaact ttctttcttg aattcttggt tctcttg

<210> 51
<211> 1191
<212> DNA
<213> Human

55 <400> 51

EP 1 586 333 A2

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccgggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggttggtct	ctgtgccact	120
	cctggaaaaa	aatgaattgg	gtaaggaaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
5	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttggtgcc	gctgccgttc	240
	aaacttgctca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcggg	gacgctcctg	acaagtcggg	360
	aatttctcta	tttctccact	gggtgcaaaga	gcggatttct	ccctgcttct	cttctgtcac	420
	ccccgtcct	ctccccagc	aggctccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
10	ccatcacaga	taaaagaaaa	atacagggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggttcttag	660
	atggaatcag	cgccggaaaa	gaacagggaag	agatgaagaa	gcaaaatcaa	caagaccagg	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaatc	tcaacgaagg	aagaggccat	tttaagaaaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaaagaaa	gaaagagcag	900
15	aagagtcaat	tgaggacatc	tatgtcaata	tccttgacct	tccaaagtcc	tacatacctt	960
	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaattaaaa	gttgaaaaag	acttgaagac	tggagaaagt	acagttctgt	1080
	cttccaatac	ctctggccat	cagatgactt	taaaagggtac	aggagtaaaa	gtttaagatg	1140
	atgggcaaaa	gtccagtgtg	ttcagtaaa	tgctaatac	aagttggagg	t	
	<210>	52					
20	<211>	1200					
	<212>	DNA					
	<213>	Human					
	<400>	52					
25	aacagggact	ctcactctat	caaccccagg	ctggagtccg	gtgcgcccac	cctggctccc	60
	tgcaacctcc	gctctccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	tttttgtaga	gacagggttt	180
	cgcttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggttgg	tttaaaaaata	attgcttttt	tattattttt	gcatttttgc	300
	accaacctta	atgctatgta	aatagttgtt	atactgttgc	ttaacaacag	tatgacaatt	360
30	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaatttc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggtctggc	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagtattgg	tacagtggaa	agagttagtg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagctc	cagttgcctc	720
35	acctgtaaaa	tgaagaact	ggataactct	taagggtcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaatgtct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
	agagatgggg	tctcactctg	tcacccagac	tgaggtacag	tgccacaatc	atagctcact	1020
40	gctgcctcaa	attcatgggc	tcaagtgatc	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatactct	tttttttttt	tctttttttt	tttttttaca	aatcagaaat	acttattttt	1200
	<210>	53					
	<211>	989					
45	<212>	DNA					
	<213>	Human					
	<400>	53					
50	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	cattttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	cttttttcaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tcaggaagtc	cagggagcct	ctacaaatgc	180
	agagtgactc	tttaccaca	taaaccttag	atacatgcaa	aaagcaggac	ccttccctca	240
	ggaatgtgcc	atttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcattg	cgtgatctca	ctcactgcaa	ttccacctcc	420
55	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttgggtcaggc	gggtctcgaa	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

EP 1 586 333 A2

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aattttccaaa caaacacat gtccacttca ctgataaaaa 720
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 ttaagatttc ttacgaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
 5 ttaatatatt tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtg c actggcgcaa 960
 gcccgcctca ccgcaatctc tgccaccgcg

<210> 54
 <211> 250
 10 <212> DNA
 <213> Human

<400> 54

catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
 agtggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 aaagggcatt ctttaggaac tgcattctgt aacccacacc ttgatccaag agctagggaa 240
 acttcagttg

<210> 55
 <211> 2270
 20 <212> DNA
 <213> Human

<400> 55

gcgcccccca gcagcgcccc cgccctccgc gccttctccg ccgggacctc gagcgaaaaga 60
 ggccccgcgc ccgcccagcc ctgcctccc tgccaccgcg gcacaccgcg ccgccacccc 120
 gaccccgctg cgacggccct gtccgctgca caccagcttg ttggcgtctt cgctcgccgcg 180
 ctgcgcccgg gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgccct 240
 tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cacctgcccc gctgcctgcc 300
 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360
 30 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
 accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacgggg 540
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
 ttcctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtcg 660
 tcaaagttac cgggcagtg tgcgaggagt gggctctgtg cgaggatagt atcaaggacc 720
 35 ccattgagga caaccagggc ctcttggca aggagctggg attcgatgcc tccgagtggt 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840
 ctgttttttg aatggagcct cgcattctat acaacccttt acaaggccag aaatgtattg 900
 ttcaaaacac ttcattggtcc cagtgtcaa agacctgtg aactggatc tccacacgag 960
 ttaccaatga caacctgag tgccgccttg tgaaagaaac ccgattttgt gaggtgcggc 1020
 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
 40 aatcccccca accagtcagg tttacttacg ctggatgttt gattgtgaag aaataccggc 1140
 ccaagtactg cggttctctg gtggacggcc gatgctgcac gccccagctg accaggactg 1200
 tgaagatgag gttccgctgc gaagatgggg agacatttcc caagaacgctc atgatgatcc 1260
 agtctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
 45 cctagacaaa caagggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggt 1440
 ggtgtgggtg atgggactca ttgtagaagg gaagccttgc tcattcttga ggagcattaa 1500
 ggtatttcga aactgccaa ggtgctgggt cggtatggca ctaatgcagc cagatttga 1560
 gaatactttg ctcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
 ttgatgactt tctgttttct gtttgtaaat tatgtgtaa gcatatttcc tctaggcttt 1680
 tttccatttt ggggttctaca gtcgtaaaag agataataag attagtttga cagtttaaa 1740
 50 cttttattcg tcttttgaca aaagtaaatg ggagggcatt ccatcccttc ctgaaggggg 1800
 aactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 ggtgttttaa gactgaatgt tttatttatt aaaatgtagc ttttggggag ggaggggaaa 1920
 tgtaatactg gaataatttg taaatgattt taattttata ttcaagtgaag agattttatt 1980
 tatggaatta accatttaat aaagaaatat ttaccttaata tctgagtgtg tgccattcgg 2040
 tattttttaga ggtgctccaa agtcattagg aacaacctag ctacagctact caattattca 2100
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
 55 ttataccttc agtagagaaa agtcttttga tataaagtaa tgtttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

EP 1 586 333 A2

5 <210> 56
 <211> 1636
 <212> DNA
 <213> Human

 <400> 56

 10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagga 60
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccg ggcggccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctccc agatggctcc 180
 tggtttgctt ggtctcaagg acactgcatc gtcaaactga tcccctggcc gttggaggag 240
 cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300
 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctggg gctggccttc 360
 agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
 gatgtctctt gctggttct tgtacggga ctcaacgat ggcagatcaa gatctggag 480
 15 gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
 agcttcacac ccagtggcag tttgattttg gtctccgct caccggataa gactcttcgc 600
 atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
 gtttactctc gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
 20 tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
 agcagtgttg tctctgtga cttctcccc gactctgccc tgcctgtcac ggcttcttac 840
 gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900
 acccaggttg acccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
 tgggcccttg aactgaaaac tccattgca tttgctcta tgaccaatgg gctttgctgc 1080
 acatttttcc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
 25 tggacagctc ctagggtcct gtectcactg aagcacttat gccggaaagc ccttcgaagt 1200
 ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260
 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
 cctgtcaaag ggagtgtgct gaataatggg ccaaacatct ggtcttgcat tgaatatgca 1380
 tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
 30 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagtgtga acttatattg 1500
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
 aagatgtgga aggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
 gacctgtgct tgcgtt

 <210> 57
 <211> 460
 <212> DNA
 35 <213> Human

 <400> 57

 40 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
 tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcagg 180
 ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
 atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
 aactgaggct gggaaagtcac atagcaagtg actggcagag ctgggactgg aacccaacca 360
 45 gcctcctaga ccacggttct toccatcaat ggaatgctag agactccagc caggtgggta 420
 ccgagctcga attcgtaatc atggtcatag ctgtttcctg

 <210> 58
 <211> 1049
 <212> DNA
 <213> Human

 50 <400> 58

 55 atctgatcaa gaatacctgc cctggtcact ctgcgatgt ttctgtccac ttgttcacat 60
 tgaggacca gatactctt tttacagagg cacttggtcg gtctaacaca gacacctcca 120
 tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gctggacta 180
 cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcaactctgaa 240
 gtcagtgtct gtgcaggtt taccgtggct ctgcattcct caggcattaa aggtcttttg 300
 ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360

5 aaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgc ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtatata aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 10 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgt cagggccaaa gagcagttgc cctccagat gctttctgtg gaggttctgca 1020
 acttcaagaa agactctggc tgttctcaa

 <210> 59
 <211> 747
 15 <212> DNA
 <213> Human

 <400> 59


 20 tttttcaaatt cacatatggc ttctttgacc ccatcaaata actttattca cacaaaacgtc 60
 ccttaatttta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaacccaag taaaccaagt aaaaaaata ttcataataa 180
 gttggttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gttaaagaag tcactgcaat gtactccccg gctctgatga 360
 25 aaagaagccc ctggcacaaa agattccagt gccctgaag aggcctccct cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 30 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcaattta gtagtaatag cggccgc

35

Claims

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiotensin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiotensin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiotensin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiotensin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiotensin/Tie receptor systems.

6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.
- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutic application.
- 15 10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
 - a) compounds which inhibit receptor tyrosine kinase activity,
 - b) compounds which inhibit ligand binding to receptors,
 - 20 c) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - 25 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
- 30 11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of
 - g) compounds which inhibit receptor tyrosine kinase activity,
 - h) compounds which inhibit ligand binding to receptors,
 - i) compounds which inhibit activation of intracellular signal pathways of the receptors,
 - 35 j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 - k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 - 40 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.
12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.
- 45 13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a
14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.
- 50 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I



I,


in which

r
n
R₃ und R₄

has the meaning of 0 to 2,

has the meaning of 0 to 2;

- a) each independently from each other have the meaning of lower alkyl,
- b) together form a bridge of general partial formula II,




II,

wherein the binding is via the two terminal C- atoms, and

m

has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III



wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T₁ and T₄;

G

has the meaning of C₁-C₆ - alkyl, C₂ - C₆ - alkylene or C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene

or C₃-C₆-alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂-, oxa (-O-), thia (-S-) or imino (-NH-), independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

5 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,


 X has the meaning of imino, oxa or thia;

 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

10 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or

15 an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof,

20 and/or a compound of genaral formula IV




in which



40 A has the meaning of group =NR²,

 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,

 Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group



55 or A, Z and R¹ together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

X

Y

p

R¹

R²

R³

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 - 3,

has the meaning of 1 - 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,


has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R¹,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of fur halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰



independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,

and/or a compound of general formula V




in which


20 R¹ has the meaning of group



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R⁸ is -CH₃, fluoro,
chloro or -CF₃

in which R⁴ is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R⁶ is
-CH₃ or chloro

R² has the meaning of pyridyl or the group



and

R³ has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/or II (4-Chlorophenyl) [4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage

EP 1 586 333 A2

of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6